Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pharvaris (PHVS), Cardiol Therapeutics (CRDL) and Fortress Biotech (FBIO) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharvaris (PHVS)
In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris, with a price target of $30.40. The company’s shares closed last Friday at $30.40.
According to TipRanks.com, Skor is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pharvaris with a $48.04 average price target, implying a 58.3% upside from current levels. In a report issued on May 12, RBC Capital also maintained a Buy rating on the stock with a $51.00 price target.
See the top stocks recommended by analysts >>
Cardiol Therapeutics (CRDL)
Canaccord Genuity analyst Edward Nash maintained a Buy rating on Cardiol Therapeutics yesterday and set a price target of $8.00. The company’s shares closed last Friday at $1.32.
According to TipRanks.com, Nash is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardiol Therapeutics with a $8.50 average price target, a 534.3% upside from current levels. In a report issued on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
Fortress Biotech (FBIO)
In a report released today, Scott Henry from Alliance Global Partners maintained a Buy rating on Fortress Biotech, with a price target of $5.00. The company’s shares closed last Friday at $2.41.
According to TipRanks.com, Henry has 0 stars on 0-5 stars ranking scale with an average return of
Fortress Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
Read More on PHVS:
Disclaimer & DisclosureReport an Issue
- Pharvaris price target raised to $33 from $31 at BofA
- Pharvaris price target lowered to $74 from $75 at Citizens
- Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
- Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
- Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
